Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease
Authors:
- 1 January 2019
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 75 (1) , 8-10
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?European Urology, 2018
- Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive DiseaseBladder Cancer, 2017
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016European Urology, 2017
- Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer GroupJournal of Clinical Oncology, 2016
- Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCGBladder Cancer, 2015
- The Response of Patients with Superficial Bladder Cancer to a Second Course of Intravesical Bacillus Calmette-GuerinJournal of Urology, 1990
- Results of 6 Weekly Intravesical Bacillus Calmette-Guerin Instillations on the Treatment of Superficial Bladder TumorsJournal of Urology, 1988
- Risks and Benefits of Repeated Courses of Intravesical Bacillus Calmette-guerin Therapy for Superficial Bladder CancerJournal of Urology, 1987